Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Thorne

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Plos One|February 4, 2014
Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutationPhillip J Whiley, Michael T Parsons, Jennifer Leary, et al.
Journal of Medical Genetics|November 5, 2015
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer familiesJun Li, Huong Meeks, Bing-Jian Feng, et al.
Molecular Oncology|July 24, 2025
Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathologyRosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee Clark, et al.
Nature Communications|March 22, 2019
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancerElizabeth L Christie, Swetansu Pattnaik, Jessica Beach, et al.
European Urology|August 27, 2014
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosisGail P Risbridger, Renea A Taylor, David Clouston, et al.
Journal of Personalized Medicine|November 4, 2015
"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the ClinicJohn P Parisot, Heather Thorne, Andrew Fellowes, et al.
BJU International|October 5, 2017
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cellsLaura H Porter, Kohei Hashimoto, Mitchell G Lawrence, et al.
Cancer Research|March 1, 2012
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer riskKevin Brennan, Montserrat Garcia-Closas, Nick Orr, et al.
Plos Genetics|October 3, 2012
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility allelesElla R Thompson, Maria A Doyle, Georgina L Ryland, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 16, 2013
Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriersEsther M John, Valerie McGuire, Duncan Thomas, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Plos One|February 4, 2014
Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutationPhillip J Whiley, Michael T Parsons, Jennifer Leary, et al.
Journal of Medical Genetics|November 5, 2015
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer familiesJun Li, Huong Meeks, Bing-Jian Feng, et al.
Molecular Oncology|July 24, 2025
Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathologyRosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee Clark, et al.
Nature Communications|March 22, 2019
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancerElizabeth L Christie, Swetansu Pattnaik, Jessica Beach, et al.
European Urology|August 27, 2014
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosisGail P Risbridger, Renea A Taylor, David Clouston, et al.
Journal of Personalized Medicine|November 4, 2015
"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the ClinicJohn P Parisot, Heather Thorne, Andrew Fellowes, et al.
BJU International|October 5, 2017
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cellsLaura H Porter, Kohei Hashimoto, Mitchell G Lawrence, et al.
Cancer Research|March 1, 2012
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer riskKevin Brennan, Montserrat Garcia-Closas, Nick Orr, et al.
Plos Genetics|October 3, 2012
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility allelesElla R Thompson, Maria A Doyle, Georgina L Ryland, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 16, 2013
Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriersEsther M John, Valerie McGuire, Duncan Thomas, et al.
Pageof 5